Nan Shan Life Insurance Co. Ltd. Purchases 195,313 Shares of Johnson & Johnson (NYSE:JNJ)

Nan Shan Life Insurance Co. Ltd. lifted its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 179.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 304,274 shares of the company's stock after acquiring an additional 195,313 shares during the quarter. Nan Shan Life Insurance Co. Ltd.'s holdings in Johnson & Johnson were worth $44,004,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Sulzberger Capital Advisors Inc. acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at approximately $453,000. Oregon Pacific Wealth Management LLC bought a new stake in Johnson & Johnson in the 4th quarter valued at about $949,000. Horan Securities Inc. raised its holdings in Johnson & Johnson by 1.3% during the fourth quarter. Horan Securities Inc. now owns 7,178 shares of the company's stock worth $1,038,000 after buying an additional 90 shares during the last quarter. Strategic Financial Concepts LLC increased its holdings in Johnson & Johnson by 57.9% during the 4th quarter. Strategic Financial Concepts LLC now owns 3,467 shares of the company's stock worth $501,000 after purchasing an additional 1,271 shares in the last quarter. Finally, KPP Advisory Services LLC lifted its position in shares of Johnson & Johnson by 4.7% during the fourth quarter. KPP Advisory Services LLC now owns 11,492 shares of the company's stock valued at $1,662,000 after purchasing an additional 515 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Insider Activity at Johnson & Johnson

In related news, VP Robert J. Decker sold 6,999 shares of the company's stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the transaction, the vice president now owns 21,001 shares in the company, valued at approximately $3,483,645.88. This represents a 25.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares of the company's stock, valued at $2,357,552.70. This trade represents a 2.60% decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Analyst Ratings Changes

Several analysts have recently issued reports on JNJ shares. Bank of America lowered their price target on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a research report on Thursday, April 10th. Morgan Stanley raised their target price on shares of Johnson & Johnson from $164.00 to $169.00 and gave the stock an "equal weight" rating in a report on Wednesday, April 16th. Stifel Nicolaus dropped their target price on shares of Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating for the company in a research report on Thursday, January 23rd. Guggenheim reissued a "neutral" rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Finally, Raymond James lowered their price objective on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a research note on Monday, April 14th. Ten research analysts have rated the stock with a hold rating, seven have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $170.88.

Johnson & Johnson Price Performance

JNJ stock opened at $148.71 on Wednesday. The company's 50-day moving average price is $157.33 and its two-hundred day moving average price is $154.14. The firm has a market cap of $357.81 billion, a P/E ratio of 22.36, a P/E/G ratio of 2.56 and a beta of 0.42. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.59 by $0.18. The company had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. On average, analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 3.50%. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend is Tuesday, May 27th. Johnson & Johnson's payout ratio is presently 57.84%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.